The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma

References

• 1  Simpson D, Keating GM. Sorafenib in hepatocellular carcinoma. Drugs68(2),251–258 (2008).
  Medline CASGoogle Scholar
• 2  McKeage K, Wagstaff AJ. Sorafenib in advanced renal cancer. Drugs67(3),475–483 (2007).
  Medline CASGoogle Scholar
• 3  Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J. Clin. Oncol.27(20),3312–3318 (2009).
  Medline CASGoogle Scholar
• 4  Alves RC, Alves D, Guz B et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann. Hepatol.10(1),21–27 (2011).
  MedlineGoogle Scholar
• 5  Keating G, Santoro A. Sorafenib. A review of its use in advanced hepatocellular carcinoma. Drugs69(2),223–240 (2009).
  Medline CASGoogle Scholar
• 6  Porta C, Bellmunt J, Eisen T et al. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev.36,16–23 (2010).
  MedlineGoogle Scholar
• 7  Janzen NK, Kim HL, Figlin RA et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am.30,843–852 (2003).
  MedlineGoogle Scholar
• 8  Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359,378–390 (2008).
  Medline CASGoogle Scholar
• 9  Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious comorbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993–1996. J. Clin. Epidemiol.52,1131–1136 (1999).
  Medline CASGoogle Scholar
• 10  Gernone A, Pagliarulo A, Pagliarulo V. Comorbidity and sorafenib (SOR) therapy in elderly patients with metastatic renal cell carcinoma. J. Clin. Oncol.29(Suppl. 7), Abstract 398 (2011).
  Google Scholar
• 11  The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14),977–986 (1993).
  MedlineGoogle Scholar
• 12  Consensus Committee. Consensus statement on the worldwide standardization of the haemoglobin A1c measurement: American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care30,2399–2400 (2007).
  MedlineGoogle Scholar
• 13  International Expert Committee. International Expert Committee report on the role of HbA1c assay in the diagnosis of diabetes. Diabetes Care32,1327–1334 (2009).
  Medline CASGoogle Scholar
• 14  WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation. WHO, Geneva, Switzerland (2006).
  Google Scholar
• 15  American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care33(Suppl. 1),S62–S69 (2010).
  MedlineGoogle Scholar
• 16  Lindblad P, Chow WH, Chan J et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologica42(10),107–112 (1999).
  Medline CASGoogle Scholar
• 17  Joh HK, Willett WC, Cho E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care34(7),1552–1556 (2011).
  MedlineGoogle Scholar
• 18  Davila JA, Morgan RO, Shaib Y et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut54,533–539 (2005).
  Medline CASGoogle Scholar
• 19  El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence. Clin. Gastroenterol. Hepatol.4(3),369–380 (2006).
  MedlineGoogle Scholar
• 20  Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer116(8),1938–1946 (2010).
  MedlineGoogle Scholar
• 21  Valter D, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol.15(20),2506–2511 (2009).
  MedlineGoogle Scholar
• 22  Lagiou P, Kuper H, Stuver SO et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J. Natl Cancer Inst.92(13),1096–1099 (2000).
  Medline CASGoogle Scholar
• 23  Polesel J, Zucchetto A, Montella M et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol.20,353–357 (2009).
  Medline CASGoogle Scholar
• 24  Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer47(9),1287–1298 (2011).
  Medline CASGoogle Scholar
• 25  Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin. Med. Insights Oncol.4,143–154 (2010).
  Medline CASGoogle Scholar
• 26  Billemont B, Medioni J, Taillade L et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer99(9),1380–1382 (2008).
  Medline CASGoogle Scholar
• 27  Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Lett. Ann. Oncol.19(4),824–825 (2008).
  Medline CASGoogle Scholar
• 28  Agostino N, Chinchilli VM, Lynch CJ et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J. Oncol. Pharm. Pract.17(3),197–202 (2011).
  Medline CASGoogle Scholar
• 29  Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol.22(8),1812–1823 (2011).
  Medline CASGoogle Scholar
• 30  Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer116(5),1272–1280 (2010).
  Medline CASGoogle Scholar
• 31  Porta C, Paglino C, Imariso I et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer11,105 (2011).
  Medline CASGoogle Scholar
• 32  Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J. Support. Oncol.9,13–23 (2011).
  Medline CASGoogle Scholar
• 33  Antonelli A, Fallahi P, Ferrari SM et al. New targeted therapies for thyroid cancer. Curr. Genomics12(8),626–631 (2011).
  Medline CASGoogle Scholar
• 34  Gradishar WJ. Sorafenib in locally advanced or metastatic breast cancer. Expert Opin. Investig. Drugs21(8),1177–1191 (2012).
  Medline CASGoogle Scholar
• 35  Posades EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park)26(3),290–301 (2012).
  MedlineGoogle Scholar
• 101  Beltramello GP, Manicardi V, Trevisan R. Consensus document of the AMD, FADOI and SID. TRIALOGUE managing hyperglycaemia in internal medicine. Instructions for use. www.siditalia.it/linee-guida.html
  Google Scholar